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How did the study come about?
A number of large population-based cardiovascular surveys
have been conducted in Norway since the beginning of the
1970s. The surveys were carried out by the National Health
Screening Service in cooperation with the universities and local
health authorities. All surveys comprised a common set of
questions, standardized anthropometric and blood pressure
measurements and non-fasting blood samples that were
analysed for serum lipids at the Ulleva˚l Hospital Laboratory.
These surveys provided considerable experience in conducting
large-scale population-based surveys, thus an important back-
ground for the Cohort of Norway (CONOR). In the late 1980s
the Research Council of Norway established a programme in
epidemiology. This also gave stimulus to the idea of establish-
ing a cohort including both core survey data and stored blood
samples. In the early 1990s, all universities, the National Health
Screening Service, The National Institute of Public Health and
the Cancer Registry discussed the possibility of a national
representative cohort.1 The issue of storing blood samples for
future analyses raised some concern and it was discussed in the
parliament. In 1994, the Ministry of Health appointed the
Steering Committee for the CONOR collaboration. In 1994–95,
the fourth round of the Tromsø Study was conducted, and
became the first survey to provide data and blood samples for
CONOR. During the years 1994–2003, a number of health
surveys that were carried out in other counties and cities also
provided similar data for the network. So far, 10 different
surveys have provided data and blood samples for CONOR
(Figure 1). The administrative responsibility for CONOR was
given to the Norwegian Institute of Public Health (NIPH) in
2002. The CONOR collaboration is currently a research
collaboration between the NIPH and the Universities of
Bergen, Oslo, Tromsø and Trondheim.
The purpose of CONOR
The CONOR cohort has not been established on the basis of any
single hypothesis but is rather a multipurpose study. The
ambition was to set up a sufficiently large enough cohort to
study aetiological factors for a wide range of diseases.
Additionally, this cohort should make it possible to describe
Norwegian men and women in terms of distribution of
exposures and health status according to time, place and
socio-economic factors.
In 2002, CONOR and the Norwegian Mother and Child study
(MoBa),2 received a 5-year grant from the Norwegian Research
Council to build a technology platform under the Functional
Genomics programme (FUGE), called the Biobanks for Health
in Norway (Biohealth) platform.3 The overall aim was to
investigate separate and combined effects of genes and
environment on the risk of disease.
Who is in the sample?
Altogether 309 742 individuals were invited to the 10 surveys
based on the 11-digit personal identifier and addresses from the
Population Registry of Norway.4 The goal is to include 200 000
participants. We defined those who attended the survey and/or
answered at least one questionnaire and signed a written
informed consent as participants. The numbers in Table 1
include individuals who participated and had given their
written consent for research and linkage to health registries.
A total of 7309 persons participated in two CONOR surveys, and
one person participated in three. Thus, the total number of
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individuals in the CONOR cohort is 173 236. The distribution of
age at the first examination and the number of deaths during
follow-up through 2003 is given in Table 2. The individual
surveys may have published papers with slightly different total
numbers. Sampling procedures differed somewhat between the
individual studies. The web site for each study contains more
detailed information (Table 1).
What has been measured?
In all the CONOR surveys, the data collection followed
a standard procedure. Letters of invitation were mailed about
2 weeks before the time of appointment and included a
questionnaire and a brochure with the aims of the study and
information about the examinations and procedures. At the
screening, this initial questionnaire was collected from the
attendees, participants underwent a physical examination and
a non-fasting blood sample was drawn. In most studies, the
participants were given one or two supplementary question-
naires, which they were instructed to fill in at home and return
by mail in pre-addressed stamped envelopes.
About 4 weeks after attending the examination, a letter with
selected results from the examination and blood tests was sent
to all participants. Those with the highest scores of cardiovas-
cular risk (a modified Framingham risk score based on
multiplying the relative risks attributable to the subject’s
gender, serum cholesterol, systolic blood pressure the number
of cigarettes currently smoked per day and family history of
Table 1 Number of invited and participating subjects in cohort of Norway (CONOR) 1994–2003
Name of the study
Year of
survey
Number
invited
Invited
age-groups
in years
Number of participantsa
Men Women Total Web address
Tromsø IV (The fourth Tromsø
Study)
1994–1995 37 558 25þ 12 797 14 128 26 925 http://uit.no/tromsoundersokelsen/tromso4/2
HUNT II (The second
North-Trøndelag Study)
1995–1997 94 196 20þ 30 441 34 576 65 017 http://www.hunt.ntnu.no/
HUSK (The Hordaland Health
Study)
1997–1999 38 587 40–44, 46–47,
70–72
11 678 13 851 25 529 http://www.uib.no/isf/husk/
Oslo II (The second Oslo Study) 2000 14 209 48–77 6919 6919 http://www.fhi.no/artikler/?id¼54685
HUBRO (The Oslo Health Study) 2000–2001 58 660 30, 31, 40, 45,
46, 59/60,
75/76
9509 11 852 21 361 http://www.fhi.no/artikler/?id¼54464
OPPHED (The Oppland and
Hedmark Health Study)
2000–2001 22 327 30, 40, 45,
60, 75
5602 6661 12 263 http://www.fhi.no/artikler/?id¼28233
Tromsø V (The fifth Tromsø
Study)
2001 10 353 30þ 3440 4457 7897 http://uit.no/tromsoundersokelsen/tromso5/2
I-HUBRO (The Oslo Immigrant
Health Study)
2002 12 088 20–60 1877 1737 3614 http://www.fhi.no/artikler/?id¼28217
TROFINN (The Troms and
Finnmark Health Study)
2002 16 229 30–77 4196 4836 9032 http://www.fhi.no/artikler/?id¼28261
MoRo II (The second part of
the Romsa˚s in Motion Study)
2003 5535 34–70 896 1093 1989 http://www.fhi.no/artikler/?id¼28254
CONOR (Cohort Norway)a 1994–2003 309 742 20–103
Sum of participants 87 355 93 191 180 546 http://www.fhi.no/artikler/?id¼28138
Sum of individuals 84 153 89 083 173 236
aNumber of participants equals those who attended the survey and agreed that information from the CONOR survey and blood samples can be
linked to other registers and used in research. A total of 7310 individuals participated in more than one survey. Thus, the total number of individuals
equals 173 236.
Figure 1 Map of Norwegian counties with location of each sub-study
included in cohort of Norway (CONOR)
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coronary heart disease) were advised to visit their own general
practitioner, and in some cases offered a follow-up examination
at the local hospital.5
Measures
Only a restricted core set of measurements and questionnaire
responses constitute the CONOR data. Most individual studies
that contribute to CONOR have more detailed measurements and
questionnaire data. In the following section we describe the key
core measurements that all studies contribute to CONOR; at the
end we briefly describe some of the additional measurements
that are in some of the contributing individual studies. All surveys
were carried out in collaboration with the National Health Screen-
ing Service, Oslo (now the NIPH). Experienced and trained
personnel conducted all procedures. Non-fasting serum total-
and HDL-cholesterol, glucose and triglycerides were measured
directly by an enzymatic method (Boehringer 148393, Boehringer-
Mannheim, Federal Republic of Germany—from 2000 Hitachi 917
auto analyzer, Roche Diagnostic, Switzerland).
The Department of Clinical Chemistry, Ulleva˚l University
Hospital, Oslo, performed all laboratory assessments except for
HUNT II (The second North-Trøndelag Study) where the analyses
were performed at the Department of Clinical Chemistry, Levanger
Hospital, Levanger. In Tromsø IV and V, cholesterol and triglycer-
ides were measured at the Department of Clinical Chemistry,
University Hospital North-Norway, Tromsø. Calibration procedures
were carried out between these laboratories in connection with the
surveys (Dr P.G. Lund-Larsen, National Health Screening Service,
personal communication). An acceptable stability of the laboratory
analyses over time in the population surveys has been reported.6
Heart rate, systolic and diastolic blood pressures were mea-
sured by an automatic device (DINAMAP, Criticon, Tampa,
FL,USA). After 2 min of seated resting, three recordings were
made at 1-min intervals. Mean values of the second and third
systolic blood pressure measurements were used in calculating
the cardiovascular risk score (CVD risk score) (Tverdal, 1989
5/id). The stability of the blood pressure measures has been
evaluated and deemed acceptable.7
Body weight (in kilograms, one decimal) and height (in
centimetres, one decimal) was measured according to a standard
protocol with the participants wearing light clothing without
shoes (manually recorded until 2000 and after that with an
electronic Height and Weight Scale). Body mass index (BMI) was
calculated as kilograms per square metre. Waist circumference
was measured at the umbilicus to the nearest centimetre and with
the subject standing and breathing normally. In obese individuals,
waist circumference was defined as the midpoint between the iliac
crest and lower margin of ribs. Hip circumference was measured
as the maximum circumference around the buttocks. Both waist
and hip were measured with a measuring tape of steel—which
was emphasized to be placed horizontally. The waist–hip
circumferences were used to calculate the waist–hip ratio.
Most individual studies that contribute to CONOR have
several additional measurements—for example, extra samples
of blood, ECG and ultrasonographic examination of carotid
artery and abdominal aorta. Four of the study sites measured
bone mineral density (DEXA and/or SXA) and have established
a research group called Norwegian Epidemiologic Osteoporosis
Studies (NOREPOS).8 Altogether, around 28 000 individuals
have had their bone mineral density measured and currently a
number of collaborative studies are carried out.
The CONOR questions
All surveys used about 50 core CONOR questions agreed upon
before the first CONOR survey in Tromsø in 1994. The exact
wording of the questions is available at the CONOR website
(http://www.fhi.no/dav/CA11310499.doc). Some questions have
been slightly modified over the years.
The CONOR questions cover the following main topics: self-
reported health and diseases such as diabetes, asthma, coronary
heart disease, stroke and mental distress, musculo-skeletal
pains, family history of disease, risk factors and lifestyle, social
network and social support, education, work and housing, some
types of occupation, use of medications and reproductive
history (women).
Several of the questions have been evaluated or validated and
deemed acceptable.9–18 The Population Registry of Norway that
was used to identify eligible subjects, contains information about
gender, date of birth, marital status, address and country of birth.
Blood samples
Blood samples were drawn from the CONOR participants. EDTA
blood for CONOR and the other sub-surveys have normally
been collected in 7 or 5 ml vacutainers. These vacutainers were
made by different manufacturers but were normally made of
polypropylene. DNA has been extracted from more than 90 000
specimens to medio 2007, and Biohealth intends to extract
DNA from all samples by Spring 2008. The extracted DNA and
an additional sample of 1.25 ml EDTA-blood will be stored at a
national biobank storage site at HUNT/NTNU biobank in
Levanger (Mid-Norway).
What has been found?
Although a number of analyses from each participating study
have been conducted, the CONOR file has only recently been
compiled and made available for research. The first CONOR
project was anchored in NOREPOS describing urban–rural
differences in forearm fractures.19 Other methodological and
validation studies have been completed as described above.
What are the main strengths and
weaknesses?
The CONOR database has several strengths: it is population
based including populations from various parts of Norway, both
rural and urban. The 11-digit personal identification number
makes it possible to link cohort participants to national health
registries. At present, several large linkages to other registers
have been or are in the process of being conducted. These
include linkages with census-based data for the whole
population and the Medical Birth Registry of Norway,
Disability Registry, Cancer Registry of Norway. Tables 2 and 3
present number of deaths and new cases of cancer in CONOR
since date of examination by linkage to the death and cancer
registries. Other large linkages include data from the
Norwegian Drug Prescription Database and information from
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health surveys in several counties in the 1970s. There are also a
number of disease registers that may be linked to the CONOR
database. Earlier this year, the government passed a new
legislation to make the national hospital discharge register
personal identifiable, which would be possible to link to
CONOR in the near future.
A major strength of CONOR is its sample size that means it
would be able to make a unique contribution to establish main
genetic effects and gene–environmental interactions, since
precise and robust estimation of these effects requires very
large sample sizes.20,21 Our aim is to reach 200 000 individuals
with blood samples and extracted DNA and we anticipate
reaching this sample size by Spring 2008. For some hypotheses,
it would be most efficient to employ a nested case control study
design within CONOR, and we anticipate several such studies
in the future. This comparatively large sample size means cases
for a number of common and less common diseases may be
identified from various sources.
There are some important weaknesses: the overall participa-
tion rate is 58% and is lowest in the surveys in Oslo and other
urban areas and became lower throughout the study period.
However, the overall participation rate is influenced by low
participation rate in those aged 430 years. The study
population is somewhat heterogeneous as it includes sampling
from 10 geographical areas with various age groups included
over a 10-year period. The number of core variables is limited,
and in some cases the wording of questions is slightly changed
over the years.
Can I get hold of the data? Where
can I find out more?
Guidelines have been developed for projects using data from
CONOR (www.fhi.no). These shall ensure that projects will
have a high scientific quality, facilitate quick publication of
results from CONOR and make the data accessible for research.
Research groups may apply for access. A project leader must be
appointed. Researchers not residing in Norway are advised to
seek contact with Norwegian counterparts. The study objectives
should be within the broader aims of CONOR. Further details
of these guidelines are provided at the CONOR website.
Applications and enquiries can be sent electronically to the
Norwegian Public Health Institute (email: conor@fhi.no).
Applications will be evaluated by the CONOR Steering
Committee.
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